DPP-4 Inhibition and TZD for DM Prevention

Stopped early · Not applicable · Has a placebo group

Conditions studied: Prediabetic State

In brief

To determine whether treatment with the diabetes medication, Januvia (sitagliptin), with or without another diabetes medicine, Actos (pioglitazone), will improve insulin secretion and insulin response individuals with Impaired Glucose Tolerance (IGT), a form of prediabetes.

Key facts

Study ID

NCT01006018

Run by

Emory University

People needed

3

Starts

2011-07-01

Expected to finish

2011-12-01

Last updated by the study team

2013-12-05

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Impaired glucose tolerance (IGT) by oral glucose tolerance test

You may not qualify if…

• History of diabetes mellitus
• History of congestive heart failure
• History of coronary artery disease or other macrovascular disease (stroke, peripheral vascular disease)
• History of liver disease (ALT or AST >2.5 times the upper limit of normals)
• History of renal disease (serum creatinine >1.5 mg/dl)
• History of severe osteoporosis (frequent fractures, failure on osteoporosis treatment)
• Current treatment with glucocorticoids
• History of immune disorder, including HIV
• Women of child-bearing age who are pregnant, desire to become pregnant, are breastfeeding, or who refuse to take the recommended birth control measures

Where it is running

• Grady Memorial Hospital — Atlanta, Georgia, United States
• Emory University Hospital — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.